PTPN22 Polymorphism and Anti-CCP Antibodies Predict Future Onset of Rheumatoid Arthritis
Author Information
Author(s): Martin Johansson, Lisbeth Ärlestig, Göran Hallmans, Solbritt Rantapää-Dahlqvist
Primary Institution: Department of Rheumatology, University Hospital, Umeå, Sweden
Hypothesis
The PTPN22 1858 polymorphism and anti-CCP antibodies can predict the future onset of rheumatoid arthritis.
Conclusion
The combination of the PTPN22 1858T variant and anti-CCP antibodies provides a strong predictor for the development of rheumatoid arthritis.
Supporting Evidence
- The PTPN22 1858T allele was associated with future onset of RA with an odds ratio of 2.29.
- The combination of the PTPN22 1858T variant and anti-CCP antibodies gave 100% specificity for diagnosing RA.
- None of the controls expressed the combination of the PTPN22 1858T variant and anti-CCP antibodies.
Takeaway
Scientists found that a specific gene change and certain antibodies can help predict if someone will get rheumatoid arthritis in the future.
Methodology
A nested case-control study was conducted using data from the Medical Biobank of Northern Sweden, analyzing the PTPN22 1858C/T polymorphism and its association with anti-CCP antibodies and rheumatoid arthritis.
Limitations
The study had a relatively small number of pre-patients identified who later developed RA, which limited the analysis of RFs and controls genotyped for HLA-SE.
Participant Demographics
The study included 92 individuals with rheumatoid arthritis (69 women and 23 men) and 368 matched controls (276 women and 92 men), all adults from Västerbotten county.
Statistical Information
P-Value
0.0005
Confidence Interval
95% CI 1.45–3.61
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website